Informace o publikaci

POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe

Autoři	ZBOŽÍNKOVÁ Zuzana BARCZYK Adam TKACOVA Ruzena VALIPOUR Arschang TUDORIC Neven ZYKOV Kirill SOMFAY Attila MIRAVITLLES Marc KOBLIZEK Vladimir
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	International Journal of chronic obstructive pulmonary disease
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.2147/COPD.S88846
Obor	Pneumologie
Klíčová slova	COPD; phenotypes; Central Europe; Eastern Europe; study; GOLD; comorbidity
Popis	Introduction: Chronic obstructive pulmonary disease (COPD) constitutes a major health challenge in Central and Eastern European (CEE) countries. However, clinical phenotypes, symptom load, and treatment habits of patients with COPD in CEE countries remain largely unknown. This paper provides a rationale for phenotyping COPD and describes the methodology of a large study in CEE. Methods/design: The POPE study is an international, multicenter, observational cross-sectional survey of patients with COPD in CEE. Participation in the study is offered to all consecutive outpatients with stable COPD in 84 centers across the CEE region if they fulfill the following criteria: age >40 years, smoking history >10 pack-years, a confirmed diagnosis of COPD with postbronchodilator FEV1/FVC <0.7, and absence of COPD exacerbation >= 4 weeks. Medical history, risk factors for COPD, comorbidities, lung function parameters, symptoms, and pharmaceutical and nonpharmaceutical treatment are recorded. The POPE project is registered in ClinicalTrials.gov with the identifier NCT02119494. Outcomes: The primary aim of the POPE study was to phenotype patients with COPD in a real-life setting within CEE countries using predefined classifications. Secondary aims of the study included analysis of differences in symptoms, and diagnostic and therapeutic behavior in participating CEE countries. Conclusion: There is increasing acceptance toward a phenotype-driven therapeutic approach in COPD. The POPE study may contribute to reveal important information regarding phenotypes and therapy in real-life CEE.